BG
Bellevue Group Portfolio holdings
AUM
$4.81B
1-Year Est. Return
29.28%
1 Year Est. Return
+29.28%
AUM
$4.54B
AUM Growth
+$74.3M
(+1.7%)
Holding
155
Top Buys
| 1 | +$39.2M | |
| 2 | +$38.3M | |
| 3 | +$36.5M | |
| 4 |
Thermo Fisher Scientific
TMO
|
+$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$17.7M |
Top Sells
| 1 | +$35.5M | |
| 2 | +$29.9M | |
| 3 | +$25.6M | |
| 4 |
Boston Scientific
BSX
|
+$20M |
| 5 |
Cencora
COR
|
+$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Sanofi
SNY
$127B
| – | – |
-16,000
|
|
||
152
Sarepta Therapeutics
SRPT
$1.97B
| – | – |
-149,113
|
|
||
153
Tenet Healthcare
THC
$17B
| – | – |
-94,722
|
|
||
154
Zai Lab
ZLAB
$2.41B
| – | – |
-20,000
|
|
||
155
Astrana Health
ASTH
$1.08B
| – | – |
-163,155
|
|